Non-CYP4F2 messenger RNAs with partial complementarity

Non-CYP4F2 mRNAs with partial complementarity refers to a group of messenger RNA transcripts that are not the intended target of a therapy but possess sequence similarity to the target region of a CYP4F2-directed drug (Ionis Pharmaceuticals, 2024). This term is primarily used in the context of antisense oligonucleotides (ASOs) or RNA interference (RNAi) therapies, where the drug's sequence may inadvertently hybridize with these non-target mRNAs (Nature Reviews Drug Discovery, 2017). Such interactions can lead to the degradation of these transcripts via RNase H or the RNA-induced silencing complex (RISC), resulting in unintended gene silencing and potential off-target toxicity (Nucleic Acids Research, 2019). CYP4F2 is a cytochrome P450 enzyme that plays a role in the metabolism of arachidonic acid to 20-HETE and the degradation of vitamin K, making it a target for cardiovascular and metabolic disease treatments (UniProt P33261). During drug development, these partially complementary sequences are identified through bioinformatics to ensure the specificity of the therapeutic agent and to minimize safety risks like hepatotoxicity (Journal of Clinical Investigation, 2021). Consequently, these molecules represent a safety liability rather than a therapeutic target.

Other names

Off-target transcriptsPartially complementary non-target mRNAsNon-target mRNA sequences

Unintended hybridization leading to RNase H-mediated degradation or translational repression of non-target transcripts.